NEW YORK (GenomeWeb News) – A set of studies stemming from the Collaborative Oncological Gene-environment Study, or COGS, have roughly doubled the number of common genetic variants implicated in prostate, breast, or ovarian cancer.

Members of the large, international consortium genotyped around 250,000 individuals for the COGS project, aimed at understanding the heritability and genetic risk profiles of the three cancers and their related subtypes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.